<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-93879" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gyrate Atrophy of the Choroid and Retina</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Elnahry</surname>
            <given-names>Ayman G.</given-names>
          </name>
          <aff>Cairo University, Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayman Elnahry declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-93879.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Gyrate atrophy of the choroid and retina is a rare autosomal recessive condition characterized by elevation of plasma ornithine levels due to deficiency of the mitochondrial enzyme ornithine aminotransferase. It is characterized mainly by the presence of specific ophthalmic manifestations; however, neurological and muscular features may also be present. This activity describes the evaluation and management of gyrate atrophy of the choroid and retina and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of gyrate atrophy of the choroid and retina.</p></list-item><list-item><p>Outline the classic presentation of a patient with gyrate atrophy of the choroid and retina.</p></list-item><list-item><p>Describe the evaluation of a patient with gyrate atrophy of the choroid and retina.</p></list-item><list-item><p>Summarize the treatment of a patient with gyrate atrophy of the choroid and retina.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93879&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93879">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-93879.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gyrate atrophy (GA) of the choroid and retina is a rare genetic disease of autosomal recessive inheritance. It primarily affects the ocular tissues and occurs due to deficiency of the enzyme ornithine aminotransferase (OAT) that leads to a 10 to 20 times increase in the plasma level of the amino acid ornithine, compared to the normal plasma levels, which is thought to result in the ocular manifestations associated with the condition.<xref ref-type="bibr" rid="article-93879.r1">[1]</xref><xref ref-type="bibr" rid="article-93879.r2">[2]</xref>&#x000a0;This occurs due to mutations in the&#x000a0;OAT gene located on chromosome 10, which results in a decrease or absence of&#x000a0;the activity of the enzyme OAT.<xref ref-type="bibr" rid="article-93879.r3">[3]</xref><xref ref-type="bibr" rid="article-93879.r4">[4]</xref>&#x000a0;The condition is characterized by the development of chorioretinal atrophic patches that start in the mid-peripheral retina in the first decade and spread centrally to the macular area, myopia, changes in the macula including cystic changes that appear in the first and second decades, and posterior subcapsular cataracts.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r6">[6]</xref>&#x000a0;Patients usually present with night blindness followed by visual field constriction and eventually diminution of central vision and blindness.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r7">[7]</xref>&#x000a0;The condition is diagnosed by the presence of the characteristic clinical picture,&#x000a0;the presence&#x000a0;of hyperornithinemia in plasma, and the detection of mutations in the OAT gene.<xref ref-type="bibr" rid="article-93879.r8">[8]</xref>&#x000a0;Treatment mainly involves dietary modifications and management of complications.<xref ref-type="bibr" rid="article-93879.r9">[9]</xref><xref ref-type="bibr" rid="article-93879.r10">[10]</xref><xref ref-type="bibr" rid="article-93879.r11">[11]</xref><xref ref-type="bibr" rid="article-93879.r6">[6]</xref></p>
      </sec>
      <sec id="article-93879.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Gyrate atrophy of the choroid and retina is a rare genetic condition of autosomal recessive inheritance&#x000a0;that results from mutations affecting the OAT gene on chromosome 10q26, leading to deficiency of the pyridoxal-dependant mitochondrial enzyme OAT which normally metabolizes the amino acid ornithine into pyrroline-5-carboxylic acid.<xref ref-type="bibr" rid="article-93879.r12">[12]</xref><xref ref-type="bibr" rid="article-93879.r13">[13]</xref>&#x000a0;Currently, there are more&#x000a0;than 60 reported mutations in the OAT gene that lead to GA.<xref ref-type="bibr" rid="article-93879.r4">[4]</xref><xref ref-type="bibr" rid="article-93879.r14">[14]</xref>&#x000a0;Defective ornithine metabolism leads to the accumulation of excessive ornithine in the plasma, urine, cerebrospinal fluid, and aqueous humor which is postulated to result in the manifestations of the condition possibly due to the toxic effects of hyperornithinemia, especially on the retinal pigment epithelial cells.<xref ref-type="bibr" rid="article-93879.r15">[15]</xref>&#x000a0;The condition can also be associated with excessive excretion of lysine and cystine in the urine with a decrease in the plasma levels of lysine, glutamine, glutamic acid, ammonia, and creatine.<xref ref-type="bibr" rid="article-93879.r16">[16]</xref><xref ref-type="bibr" rid="article-93879.r17">[17]</xref>&#x000a0;Although the OAT enzyme is expressed in most tissues, the main pathological manifestations of the condition are those involving the eye.<xref ref-type="bibr" rid="article-93879.r16">[16]</xref><xref ref-type="bibr" rid="article-93879.r18">[18]</xref></p>
      </sec>
      <sec id="article-93879.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Gyrate atrophy is a rare condition that, for unknown reasons,&#x000a0;is reported to be particularly prevalent in Finland&#x000a0;but has been reported in many other countries of the world including the USA, Japan, Germany, UK, India, China, Australia, France, Tunisia, Egypt, Korea, Brazil, Nepal, and Turkey.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r19">[19]</xref><xref ref-type="bibr" rid="article-93879.r7">[7]</xref><xref ref-type="bibr" rid="article-93879.r20">[20]</xref><xref ref-type="bibr" rid="article-93879.r21">[21]</xref><xref ref-type="bibr" rid="article-93879.r22">[22]</xref><xref ref-type="bibr" rid="article-93879.r23">[23]</xref><xref ref-type="bibr" rid="article-93879.r24">[24]</xref><xref ref-type="bibr" rid="article-93879.r25">[25]</xref><xref ref-type="bibr" rid="article-93879.r26">[26]</xref><xref ref-type="bibr" rid="article-93879.r6">[6]</xref><xref ref-type="bibr" rid="article-93879.r27">[27]</xref><xref ref-type="bibr" rid="article-93879.r28">[28]</xref><xref ref-type="bibr" rid="article-93879.r29">[29]</xref><xref ref-type="bibr" rid="article-93879.r30">[30]</xref>&#x000a0;In Finland, the prevalence is estimated to be around 1 in 50,000.<xref ref-type="bibr" rid="article-93879.r31">[31]</xref>&#x000a0;Myopia, night blindness, and visual field affection associated with the condition usually start in the first decade of life followed by a diminution of vision due to macular affection and cataract formation that usually follows&#x000a0;in the second decade, however, the onset of central vision loss is highly variable and can occur at any age according to a Finnish study.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref>&#x000a0;Some studies have shown that females may retain larger visual fields when compared to males, with preservation of night vision; however, other studies have shown that the visual field is equally affected in both males and females.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r32">[32]</xref><xref ref-type="bibr" rid="article-93879.r7">[7]</xref>&#x000a0;In a study comparing the natural history of Japanese patients to Finnish patients, there was a worse visual function in Japanese patients, which suggests that the natural history of the condition could be variable among patients from different populations.<xref ref-type="bibr" rid="article-93879.r7">[7]</xref>&#x000a0;Patients, however, usually&#x000a0;have worse than 20/200 vision between 40 and 55 years of age.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref></p>
      </sec>
      <sec id="article-93879.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Deficiency of the pyridoxal-dependant mitochondrial enzyme OAT, which normally metabolizes the amino acid ornithine into pyrroline-5-carboxylic acid, leads to accumulation of ornithine in the plasma, urine, cerebrospinal fluid, and aqueous humor of patients with GA which is thought to result in the manifestations of the condition possibly due to the toxic effects of hyperornithinemia, especially on the retinal pigment epithelial cells, leading to progressive chorioretinal atrophy.<xref ref-type="bibr" rid="article-93879.r12">[12]</xref><xref ref-type="bibr" rid="article-93879.r13">[13]</xref><xref ref-type="bibr" rid="article-93879.r15">[15]</xref>&#x000a0;Indeed, in a mouse model of GA, there was histopathologic evidence that the RPE is the initial site of damage in GA.<xref ref-type="bibr" rid="article-93879.r33">[33]</xref>&#x000a0;OAT is expressed at high levels in the RPE and a lower level in the photoreceptors, and the RPE could be especially sensitive to ornithine accumulation in the case of OAT deficiency.<xref ref-type="bibr" rid="article-93879.r33">[33]</xref><xref ref-type="bibr" rid="article-93879.r34">[34]</xref><xref ref-type="bibr" rid="article-93879.r35">[35]</xref>&#x000a0;RPE damage and atrophy may then lead to choriocapillaris atrophy leading to the characteristic chorioretinal degenerative patches seen in GA.<xref ref-type="bibr" rid="article-93879.r36">[36]</xref>&#x000a0;Damage to photoreceptors&#x000a0;in patients with GA could be the result of a&#x000a0;combination of mechanisms, including direct toxicity from hyperornithinemia, damage from toxic&#x000a0;residues produced by degenerating RPE cells, the inability of RPE cells to provide&#x000a0;normal nutrition to&#x000a0;the photoreceptors, reduced nutrition&#x000a0;due to atrophy of the&#x000a0;choriocapillaris, and breakdown of the blood-retinal barrier leading to an impaired photoceptor microenvironment that affects their normal function.<xref ref-type="bibr" rid="article-93879.r33">[33]</xref>&#x000a0;This leads to a progressive deterioration of the visual field and, eventually, central visual acuity.</p>
        <p>Other biochemical findings associated with GA include&#x000a0;excessive excretion of lysine and cystine in the urine with a decrease in the plasma levels of lysine, ammonia, glutamine, and creatine.<xref ref-type="bibr" rid="article-93879.r16">[16]</xref><xref ref-type="bibr" rid="article-93879.r37">[37]</xref>&#x000a0;Several&#x000a0;manifestations of GA, particularly central nervous system manifestations such as mental retardation and epilepsy, together with the associated muscle findings, may occur due to the secondary phosphocreatine deficiency that results from the inhibition of creatine synthesis due to the hyperornithinemia.<xref ref-type="bibr" rid="article-93879.r38">[38]</xref><xref ref-type="bibr" rid="article-93879.r39">[39]</xref>&#x000a0;This energy deficiency may also affect the function of the RPE, leading to chorioretinal atrophy.<xref ref-type="bibr" rid="article-93879.r38">[38]</xref></p>
      </sec>
      <sec id="article-93879.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathologic studies of GA are rare. In a postmortem study of a patient with pyridoxine-responsive GA, the&#x000a0;retina showed&#x000a0;focal areas of&#x000a0;atrophy of the photoreceptors&#x000a0;with hyperplasia of the adjacent RPE. An&#x000a0;abrupt transition from the almost-normal retina to the zone of the almost totally atrophic retina, RPE, and choroid was present in the retinal mid-periphery. Examination by electron microscopy&#x000a0;revealed abnormalities in the mitochondria of the corneal endothelium and the non-pigmented epithelium of the ciliary body. There were also similar, albeit less severe, mitochondrial abnormalities&#x000a0;affecting the photoreceptors.<xref ref-type="bibr" rid="article-93879.r40">[40]</xref></p>
        <p>In an adult domestic cat with a condition analogous to GA characterized by OAT deficiency and plasma hyperornithinemia, a postmortem study revealed atrophy of the RPE and photoreceptors throughout the fundus with&#x000a0;an abnormal&#x000a0;and discontinuous choriocapillaris layer.<xref ref-type="bibr" rid="article-93879.r41">[41]</xref></p>
        <p>In a study of&#x000a0;OAT-deficient GA&#x000a0;mouse models developed by gene targeting, there was marked swelling of the RPE cells with&#x000a0;irregular shape&#x000a0;and engorgement in mice on a standard diet.&#x000a0;There was also an absence of the outer segments of photoreceptors, while the inner segments were disorganized and shortened. The outer nuclear layer was also&#x000a0;markedly reduced&#x000a0;in thickness. These changes were not apparent in mice on an arginine-restricted diet. The findings were also confirmed by electron microscopy.<xref ref-type="bibr" rid="article-93879.r15">[15]</xref></p>
        <p>Muscle biopsy of patients with GA typically shows gross fatty changes with type 2 muscle fiber atrophy and tubular aggregates.<xref ref-type="bibr" rid="article-93879.r42">[42]</xref></p>
      </sec>
      <sec id="article-93879.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with gyrate atrophy of the choroid and retina usually present with night blindness and progressive visual field constriction in their first decade of life that occurs due to progressive peripheral chorioretinal degeneration.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref>&#x000a0;A family history of the condition may sometimes be present and lead to the early detection of the condition through screening in early childhood. Gradually progressive diminution of central visual acuity usually follows these manifestations,&#x000a0;occurring later in the first or second decade due to the development of macular changes and posterior subcapsular cataracts.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r6">[6]</xref>&#x000a0;Macular changes associated with GA include intraretinal cystic spaces, cystoid macular edema, foveoschisis, epiretinal membrane, and atrophy.<xref ref-type="bibr" rid="article-93879.r6">[6]</xref><xref ref-type="bibr" rid="article-93879.r43">[43]</xref><xref ref-type="bibr" rid="article-93879.r26">[26]</xref>&#x000a0;Myopia is also a commonly associated feature with the condition. Complications such as a macular hole and subfoveal choroidal neovascularization can also occur but lead to a more severe and acute&#x000a0;diminution of central visual acuity.<xref ref-type="bibr" rid="article-93879.r44">[44]</xref><xref ref-type="bibr" rid="article-93879.r45">[45]</xref>&#x000a0;Most patients will usually become legally blind (vision less than 20/200) between 40 and 55 years of age due to the late macular involvement by the chorioretinal atrophy.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref></p>
        <p>On ophthalmoscopy, the peripheral chorioretinal degeneration appears as discrete scalloped areas of chorioretinal atrophy that progressively coalesce together and have pigmented edges with visible large choroidal vessels underneath.<xref ref-type="bibr" rid="article-93879.r1">[1]</xref>&#x000a0;These atrophic patches usually start in the retinal mid-periphery but later spread to the macular area centrally and to the ora serrata peripherally to involve the whole retina with resultant visual field deterioration.<xref ref-type="bibr" rid="article-93879.r1">[1]</xref><xref ref-type="bibr" rid="article-93879.r5">[5]</xref>&#x000a0;They can also be associated with peripapillary atrophy. Retinal crystals may also be present.<xref ref-type="bibr" rid="article-93879.r1">[1]</xref>&#x000a0;The&#x000a0;normal foveal reflex may&#x000a0;not be apparent due to the associated macular cystic changes. Cataract associated with GA is usually of the posterior subcapsular type and is best appreciated by the slit-lamp biomicroscopy or direct ophthalmoscopy using the red reflex. Choroidal neovascularization is suspected by the presence of a subretinal greyish-yellow lesion with surrounding subretinal fluid, hemorrhage, and exudates.</p>
        <p>Although ophthalmic features are the main manifestations of GA, several central nervous system manifestations may also be associated with the condition, including aggressive behavior, mental retardation, and epilepsy.<xref ref-type="bibr" rid="article-93879.r38">[38]</xref>&#x000a0;Peripheral nervous system abnormalities have also been reported, and patients may occasionally have muscular weakness.<xref ref-type="bibr" rid="article-93879.r46">[46]</xref><xref ref-type="bibr" rid="article-93879.r39">[39]</xref><xref ref-type="bibr" rid="article-93879.r42">[42]</xref></p>
      </sec>
      <sec id="article-93879.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of gyrate atrophy of the choroid and retina depends on the presence of the characteristic clinical features of the condition and the presence of elevated plasma ornithine level, which is essential for the diagnosis of the condition and is usually 10 to 20 times&#x000a0;higher than the normal plasma ornithine level.<xref ref-type="bibr" rid="article-93879.r1">[1]</xref><xref ref-type="bibr" rid="article-93879.r2">[2]</xref><xref ref-type="bibr" rid="article-93879.r8">[8]</xref>&#x000a0;Other laboratory findings include&#x000a0;excessive excretion of lysine and cystine in the urine with a decrease in the plasma levels of lysine, glutamine, and creatine.<xref ref-type="bibr" rid="article-93879.r16">[16]</xref>&#x000a0;Deficiency of the OAT enzyme activity can also be demonstrated in cultured skin fibroblasts of patients, which&#x000a0;may also be partially deficient in carriers.<xref ref-type="bibr" rid="article-93879.r13">[13]</xref><xref ref-type="bibr" rid="article-93879.r47">[47]</xref>&#x000a0;There are currently more&#x000a0;than 60 known mutations in the OAT gene that lead to GA, and the detection of these mutations can help confirm the diagnosis.<xref ref-type="bibr" rid="article-93879.r4">[4]</xref><xref ref-type="bibr" rid="article-93879.r14">[14]</xref>&#x000a0;Because the condition is inherited in an autosomal recessive manner, it is important to screen the relatives of patients, especially their siblings, since early treatment may result in better long-term visual outcomes. Patients with GA have been found to have abnormally slow background electroencephalogram activity with focal and epileptogenic lesions, and some patients may also have mental retardation, aggressive behavior, or epilepsy.<xref ref-type="bibr" rid="article-93879.r38">[38]</xref><xref ref-type="bibr" rid="article-93879.r48">[48]</xref>&#x000a0;Some patients also show degenerative lesions and atrophic changes in brain magnetic resonance imaging with severe creatine deficiency detected on brain magnetic resonance spectroscopy.<xref ref-type="bibr" rid="article-93879.r38">[38]</xref><xref ref-type="bibr" rid="article-93879.r48">[48]</xref>&#x000a0;Electromyography may also be abnormal with a myopathic pattern, and muscle biopsy may show atrophy, which may also be related to creatine deficiency.<xref ref-type="bibr" rid="article-93879.r39">[39]</xref></p>
        <p>Regarding the <bold>ophthalmic evaluation of the condition</bold>, fluorescein angiography of patients with GA shows prominent retinal pigment epithelium (RPE) transmission window defects which start in the peripheral retina and correspond to the areas of RPE and choriocapillaris atrophy that characterize the disease with a hyperfluorescent lining along the borders of these defects. Large choroidal vessels are clearly seen through these defects. These defects gradually enlarge in size on follow-up and progress to coalesce together.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref>&#x000a0;Some patients also have cystoid macular edema associated with macular leakage. Others, such as patients with foveoschisis, do not have macular leakage.<xref ref-type="bibr" rid="article-93879.r22">[22]</xref>&#x000a0;Later, the macula can also be involved with chorioretinal atrophy.<xref ref-type="bibr" rid="article-93879.r1">[1]</xref><xref ref-type="bibr" rid="article-93879.r49">[49]</xref>&#x000a0;Fluorescein angiography can also demonstrate leakage in cases of GA complicated by choroidal neovascularization.<xref ref-type="bibr" rid="article-93879.r50">[50]</xref><xref ref-type="bibr" rid="article-93879.r51">[51]</xref></p>
        <p>GA can also be evaluated and followed up using ultra-widefield imaging, which allows superior imaging of the retinal periphery simultaneously with the posterior pole.<xref ref-type="bibr" rid="article-93879.r22">[22]</xref><xref ref-type="bibr" rid="article-93879.r52">[52]</xref>&#x000a0;Electroretinography (ERG) reveals diminished a and b wave responses of both rods and cones, which become undetectable in advanced disease; however, a nearly normal ERG&#x000a0;in association with GA has also been reported.<xref ref-type="bibr" rid="article-93879.r21">[21]</xref><xref ref-type="bibr" rid="article-93879.r53">[53]</xref>&#x000a0; There are also abnormalities detected in the electrooculography and dark adaptometry of patients.<xref ref-type="bibr" rid="article-93879.r54">[54]</xref></p>
        <p>Visual field testing is useful in follow-up using both static and kinetic perimetry and shows progressive visual field constriction and loss of sensitivity with age, which can be slowed with&#x000a0;appropriate treatment.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r7">[7]</xref><xref ref-type="bibr" rid="article-93879.r55">[55]</xref>&#x000a0;The visual field is also important for consideration for driving and to determine the visual disability status. Microperimetry, which applies targeted stimuli to discrete areas of the retina, may also be useful in testing macular sensitivity and function, which depends on the severity of macular affection.<xref ref-type="bibr" rid="article-93879.r56">[56]</xref></p>
        <p>Fundus autofluorescence, which is an indicator of RPE structure, may help demonstrate and follow up areas of chorioretinal atrophy as characteristic hypoautofluorescent areas.<xref ref-type="bibr" rid="article-93879.r56">[56]</xref></p>
        <p>Optical coherence tomography is useful in the evaluation of the macular area and can show variable features including intraretinal cystic spaces.<xref ref-type="bibr" rid="article-93879.r6">[6]</xref>&#x000a0;cystoid macular edema,<xref ref-type="bibr" rid="article-93879.r43">[43]</xref>&#x000a0;foveoschisis,<xref ref-type="bibr" rid="article-93879.r26">[26]</xref>&#x000a0;macular hole,<xref ref-type="bibr" rid="article-93879.r44">[44]</xref>&#x000a0;choroidal neovascularization,<xref ref-type="bibr" rid="article-93879.r45">[45]</xref>&#x000a0;epiretinal membranes,<xref ref-type="bibr" rid="article-93879.r56">[56]</xref>&#x000a0;foveal thinning,<xref ref-type="bibr" rid="article-93879.r26">[26]</xref>&#x000a0;outer retinal tubulations,<xref ref-type="bibr" rid="article-93879.r56">[56]</xref>&#x000a0;and choroidal thinning.<xref ref-type="bibr" rid="article-93879.r56">[56]</xref>&#x000a0;Optical coherence tomography angiography findings in patients with GA have been recently described and include superficial and deep retinal ischemia,<xref ref-type="bibr" rid="article-93879.r6">[6]</xref>&#x000a0;perifoveal deep retinal microvascular alterations,<xref ref-type="bibr" rid="article-93879.r26">[26]</xref>&#x000a0;enlargement of the foveal avascular zone at the level of the superficial and deep capillary plexuses that correlates with foveal cyst size,<xref ref-type="bibr" rid="article-93879.r57">[57]</xref>&#x000a0;and decreased macular vascular density.<xref ref-type="bibr" rid="article-93879.r58">[58]</xref></p>
      </sec>
      <sec id="article-93879.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of gyrate atrophy consists mainly of dietary modifications to help lower the elevated systemic ornithine levels. The restriction of arginine in the diet, the precursor amino acid for ornithine, has been found to effectively lower plasma ornithine levels and to retard the progression of chorioretinal degeneration in both human and GA mouse models.<xref ref-type="bibr" rid="article-93879.r9">[9]</xref><xref ref-type="bibr" rid="article-93879.r59">[59]</xref><xref ref-type="bibr" rid="article-93879.r54">[54]</xref><xref ref-type="bibr" rid="article-93879.r60">[60]</xref><xref ref-type="bibr" rid="article-93879.r61">[61]</xref>&#x000a0;Some patients, however, continue to develop progressive chorioretinal degeneration and electroretinographic changes despite lowered plasma ornithine levels following arginine restriction, which could be due to the genetic heterogeneity associated with the condition.<xref ref-type="bibr" rid="article-93879.r62">[62]</xref>&#x000a0;Food rich in arginine that should be avoided or reduced in the diet includes nuts, seeds, cereal, dairy products, seafood, meat, chicken, watermelon, and chocolate.<xref ref-type="bibr" rid="article-93879.r37">[37]</xref><xref ref-type="bibr" rid="article-93879.r63">[63]</xref></p>
        <p>Some patients may also benefit from vitamin B6 supplementation in lowering their plasma ornithine levels, which acts by increasing the activity of the pyridoxine-dependant OAT enzyme, while other patients do not.<xref ref-type="bibr" rid="article-93879.r47">[47]</xref><xref ref-type="bibr" rid="article-93879.r64">[64]</xref>&#x000a0;These are known as pyridoxine responders and non-responders, respectively, which has been proven by both in vivo and in vitro methods.<xref ref-type="bibr" rid="article-93879.r60">[60]</xref>&#x000a0;This is&#x000a0;possibly due to the different mutations that affect the OAT gene.<xref ref-type="bibr" rid="article-93879.r54">[54]</xref><xref ref-type="bibr" rid="article-93879.r64">[64]</xref><xref ref-type="bibr" rid="article-93879.r60">[60]</xref>&#x000a0;The dose of vitamin B6 supplementation used for patients with GA in studies is variable and has ranged from&#x000a0;around 120 to 600 mg/day.<xref ref-type="bibr" rid="article-93879.r65">[65]</xref><xref ref-type="bibr" rid="article-93879.r66">[66]</xref></p>
        <p>Creatine supplementation may also have a role in retarding the chorioretinal degeneration and in improving neurological and muscular manifestations.<xref ref-type="bibr" rid="article-93879.r54">[54]</xref><xref ref-type="bibr" rid="article-93879.r67">[67]</xref><xref ref-type="bibr" rid="article-93879.r68">[68]</xref>&#x000a0;Other dietary modifications that could be of benefit include proline and lysine supplementation.<xref ref-type="bibr" rid="article-93879.r7">[7]</xref><xref ref-type="bibr" rid="article-93879.r54">[54]</xref></p>
        <p>Examination of the fundus of the family members is very crucial to detect the disease in an early stage and to start intervention early so that the methods to reduce progression can be tried.</p>
        <p>Refraction and low vision aid form an important part of management and may improve the quality of life of the patient.</p>
        <p>Treatment of cystoid macular edema and intraretinal cystic spaces associated with GA includes restriction of arginine in diet, vitamin B6 supplementation,<xref ref-type="bibr" rid="article-93879.r69">[69]</xref>&#x000a0;topical and oral carbonic anhydrase inhibitors, topical non-steroidal anti-inflammatory drugs,<xref ref-type="bibr" rid="article-93879.r70">[70]</xref><xref ref-type="bibr" rid="article-93879.r71">[71]</xref>&#x000a0;intravitreal or subtenon steroid injections which, however, carry the risk of cataract progression and intraocular pressure elevation, and intravitreal antivascular endothelial growth factor injections.<xref ref-type="bibr" rid="article-93879.r6">[6]</xref><xref ref-type="bibr" rid="article-93879.r72">[72]</xref><xref ref-type="bibr" rid="article-93879.r30">[30]</xref><xref ref-type="bibr" rid="article-93879.r73">[73]</xref><xref ref-type="bibr" rid="article-93879.r28">[28]</xref><xref ref-type="bibr" rid="article-93879.r74">[74]</xref>&#x000a0;In cases of foveoschisis with no apparent macular leakage on fluorescein angiography, carbonic anhydrase inhibitors could be used.</p>
        <p>Treatment of ocular complications of GA includes cataract surgery for visually significant cataract which may also be associated with zonular weakness,<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r75">[75]</xref>&#x000a0;pars plana vitrectomy for macular holes,<xref ref-type="bibr" rid="article-93879.r44">[44]</xref>&#x000a0;rhegmatogenous retinal detachments,<xref ref-type="bibr" rid="article-93879.r76">[76]</xref>&#x000a0;and vitreous hemorrhage,<xref ref-type="bibr" rid="article-93879.r77">[77]</xref>&#x000a0;and intravitreal antivascular endothelial growth factor injections for choroidal neovascularization.<xref ref-type="bibr" rid="article-93879.r45">[45]</xref><xref ref-type="bibr" rid="article-93879.r50">[50]</xref></p>
      </sec>
      <sec id="article-93879.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of gyrate atrophy includes the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Choroideremia <xref ref-type="bibr" rid="article-93879.r78">[78]</xref></p>
          </list-item>
          <list-item>
            <p>Retinitis pigmentosa <xref ref-type="bibr" rid="article-93879.r79">[79]</xref></p>
          </list-item>
          <list-item>
            <p>Congenital stationary night blindness <xref ref-type="bibr" rid="article-93879.r80">[80]</xref></p>
          </list-item>
          <list-item>
            <p>X-linked retinoschisis <xref ref-type="bibr" rid="article-93879.r81">[81]</xref></p>
          </list-item>
          <list-item>
            <p>Bietti crystalline dystrophy <xref ref-type="bibr" rid="article-93879.r82">[82]</xref></p>
          </list-item>
          <list-item>
            <p>Pigmented paravenous retinochoroidal atrophy <xref ref-type="bibr" rid="article-93879.r83">[83]</xref></p>
          </list-item>
          <list-item>
            <p>Bifocal chorioretinal atrophy <xref ref-type="bibr" rid="article-93879.r84">[84]</xref></p>
          </list-item>
          <list-item>
            <p>Pathological myopia <xref ref-type="bibr" rid="article-93879.r85">[85]</xref></p>
          </list-item>
          <list-item>
            <p>Choroidal sclerosis <xref ref-type="bibr" rid="article-93879.r86">[86]</xref></p>
          </list-item>
          <list-item>
            <p>Gyrate atrophy-like phenotypes with normal plasma ornithine <xref ref-type="bibr" rid="article-93879.r87">[87]</xref><xref ref-type="bibr" rid="article-93879.r88">[88]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Extensive paving stone (cobblestone) degeneration, which however is peripheral</p>
          </list-item>
        </list>
        <p>These conditions can be differentiated from GA on the basis of the patient's history, inheritance pattern, clinical picture, laboratory findings, genetic analysis, electrophysiology, and multimodal imaging analysis.</p>
      </sec>
      <sec id="article-93879.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Patients with Gyrate atrophy, especially children, who are undergoing arginine restriction in their diet with low total protein intake should receive enough calories in their diet supplemented by essential amino acids, vitamins, and minerals to avoid malnutrition and excessive break down of their endogenous proteins.<xref ref-type="bibr" rid="article-93879.r37">[37]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-93879.s12" sec-type="Staging">
        <title>Staging</title>
        <p>Four stages of gyrate atrophy have been described according to the disease progression&#x000a0;<xref ref-type="bibr" rid="article-93879.r1">[1]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I is characterized by sharply defined and separate areas of peripheral chorioretinal atrophy with a normal disc, macula, and retinal vasculature, and concentric visual field limitation.</p>
          </list-item>
          <list-item>
            <p>Stage II is characterized by sharp areas of chorioretinal atrophy that become more fused and spread towards the posterior pole with narrower vessels, peripapillary degeneration, and similar concentric field limitation as stage I.</p>
          </list-item>
          <list-item>
            <p>Stage III is characterized by a large area of peripapillary degeneration, with an annular zone of a functioning retina between it and the peripheral degeneration, and a pale optic disc with narrower vessels. The macula is still spared with fine pigmentation, but the visual field is more deteriorated.</p>
          </list-item>
          <list-item>
            <p>Stage IV is characterized by a posterior pole that is completely atrophic with only a small functioning macular area and an extremely narrow retinal vasculature. Some patients also developed pigmentation with peripheral crystals.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93879.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with GA usually present with progressive night blindness and visual field constriction that starts in the first decade due to progressive chorioretinal degeneration, which can usually be slowed down by arginine restriction in their diet and vitamin B6 supplementation occasionally leading to a picture similar to early retinitis pigmentosa.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r55">[55]</xref>&#x000a0;This is followed by a diminution of the central visual acuity, which usually occurs in the first or second decade due to progressive macular changes and cataract formation, which can be managed by treatment of the macular conditions and cataract extraction, respectively, leading to visual acuity improvement.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r6">[6]</xref>&#x000a0;Irreversible loss of vision and blindness (vision less than 20/200) occurs when the chorioretinal atrophy reaches the central macular area, which usually occurs between 40 and 55 years of age.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref>&#x000a0;This, however, can be variable depending on several factors, including treatment.<xref ref-type="bibr" rid="article-93879.r5">[5]</xref><xref ref-type="bibr" rid="article-93879.r55">[55]</xref>&#x000a0;The development of certain complications associated with GA such as macular holes, subfoveal choroidal neovascularization, and retinal detachment can lead to an earlier and more severe loss of vision.</p>
      </sec>
      <sec id="article-93879.s14" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Macular complications
<list list-type="bullet"><list-item><p>Cystoid macular edema <xref ref-type="bibr" rid="article-93879.r69">[69]</xref></p></list-item><list-item><p>Foveal thinning</p></list-item><list-item><p>Epiretinal membrane</p></list-item><list-item><p>Intraretinal cystic spaces <xref ref-type="bibr" rid="article-93879.r6">[6]</xref></p></list-item><list-item><p>Foveoschisis <xref ref-type="bibr" rid="article-93879.r22">[22]</xref></p></list-item><list-item><p>Macular hole <xref ref-type="bibr" rid="article-93879.r89">[89]</xref></p></list-item><list-item><p>Choroidal neovascularization <xref ref-type="bibr" rid="article-93879.r45">[45]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Vitreoretinal complications
<list list-type="bullet"><list-item><p>Vitreous hemorrhage <xref ref-type="bibr" rid="article-93879.r77">[77]</xref></p></list-item><list-item><p>Intraocular lens dislocation <xref ref-type="bibr" rid="article-93879.r75">[75]</xref></p></list-item><list-item><p>Rhegmatogenous retinal detachment <xref ref-type="bibr" rid="article-93879.r76">[76]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Neurological complications
<list list-type="bullet"><list-item><p>Mental retardation <xref ref-type="bibr" rid="article-93879.r38">[38]</xref></p></list-item><list-item><p>Speech defects <xref ref-type="bibr" rid="article-93879.r61">[61]</xref></p></list-item><list-item><p>Epilepsy <xref ref-type="bibr" rid="article-93879.r38">[38]</xref></p></list-item><list-item><p>Peripheral neuropathy <xref ref-type="bibr" rid="article-93879.r46">[46]</xref></p></list-item><list-item><p>Muscular weakness <xref ref-type="bibr" rid="article-93879.r42">[42]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93879.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients and their parents must be educated about the condition and the importance of long-term compliance with dietary modifications, including the restriction of arginine in their diet since this has been shown to influence the visual function of the patients greatly. Screening of family members of patients is also very important to allow dietary measures to be implemented at an early age since this was also shown to influence the visual outcome greatly.<xref ref-type="bibr" rid="article-93879.r55">[55]</xref></p>
      </sec>
      <sec id="article-93879.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The proper management of gyrate atrophy of the choroid and retina requires the combined efforts of pediatricians, ophthalmologists, neurologists, geneticists, dieticians, and other health professionals. Only effective interprofessional communication between these health care providers&#x000a0;across a wide range of&#x000a0;disciplines, and with patients and their parents, can ensure that proper care is delivered to these patients. The currently most effective approach in the management of GA is&#x000a0;the early diagnosis of the condition followed by dietary modifications, specifically&#x000a0;the restriction of arginine&#x000a0;in the diet, and treatment of complications.<xref ref-type="bibr" rid="article-93879.r55">[55]</xref>&#x000a0;This can be achieved by the early screening and referral of patients followed by proper patient education, evidence-based management, and long-term follow up. Currently, however, most of the evidence regarding the treatment of this rare autosomal recessive condition and its complications comes from historical cohort studies and case series. [Level 4 and 5]</p>
      </sec>
      <sec id="article-93879.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93879&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93879">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/gyrate-atrophy-of-the-choroid-and-retina/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=93879">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/93879/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=93879">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-93879.s18">
        <fig id="article-93879.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Optical coherence tomography of the macula showing intraretinal cystic spaces in a 12-year-old boy with gyrate atrophy of the choroid and retina. Contributed by Ayman Elnahry, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Statpearl__OCT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-93879.s19">
        <fig id="article-93879.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Fundus fluorescein angiography of a child with gyrate atrophy showing scalloped areas of retinal pigment epithelium and choriocapillaris atrophy with visible large choroidal vessels and macular sparing Contributed by Ayman Elnahry, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="FFA__of__gyrate__atrophy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-93879.s20">
        <title>References</title>
        <ref id="article-93879.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina associated with hyperornithinaemia.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1974</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">4841281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Takki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Raised plasma-ornithine and gyrate atrophy of the choroid and retina.</article-title>
            <source>Lancet</source>
            <year>1973</year>
            <month>May</month>
            <day>12</day>
            <volume>1</volume>
            <issue>7811</issue>
            <fpage>1031</fpage>
            <page-range>1031-3</page-range>
            <pub-id pub-id-type="pmid">4122112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Del Valle</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>A specific enzyme defect in gyrate atrophy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1978</year>
            <month>Feb</month>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-4</page-range>
            <pub-id pub-id-type="pmid">623190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michaud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brody</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Steel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fontaine</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Strand-separating conformational polymorphism analysis: efficacy of detection of point mutations in the human ornithine delta-aminotransferase gene.</article-title>
            <source>Genomics</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>389</fpage>
            <page-range>389-94</page-range>
            <pub-id pub-id-type="pmid">1612597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takki</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Milton</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>The natural history of gyrate atrophy of the choroid and retina.</article-title>
            <source>Ophthalmology</source>
            <year>1981</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>292</fpage>
            <page-range>292-301</page-range>
            <pub-id pub-id-type="pmid">7254775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elnahry</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Abdel-Kader</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab for the treatment of intraretinal cystic spaces in a patient with gyrate atrophy of the choroid and retina.</article-title>
            <source>Ophthalmic Genet</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>759</fpage>
            <page-range>759-762</page-range>
            <pub-id pub-id-type="pmid">30335551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayasaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shiono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sasayama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Akiya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hayakawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyake</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohba</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina: 15 Japanese patients.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>8</issue>
            <fpage>612</fpage>
            <page-range>612-4</page-range>
            <pub-id pub-id-type="pmid">3741829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bargum</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Differential diagnosis of normoornithinaemic gyrate atrophy of the choroid and retina.</article-title>
            <source>Acta Ophthalmol (Copenh)</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-73</page-range>
            <pub-id pub-id-type="pmid">3776498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina. Long-term reduction of ornithine slows retinal degeneration.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>109</volume>
            <issue>11</issue>
            <fpage>1539</fpage>
            <page-range>1539-48</page-range>
            <pub-id pub-id-type="pmid">1755734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weleber</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kennaway</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Clinical trial of vitamin B6 for gyrate atrophy of the choroid and retina.</article-title>
            <source>Ophthalmology</source>
            <year>1981</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>316</fpage>
            <page-range>316-24</page-range>
            <pub-id pub-id-type="pmid">6789268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>de Monasterio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brusilow</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Visual results of a long-term trial of a low-arginine diet in gyrate atrophy of choroid and retina.</article-title>
            <source>Ophthalmology</source>
            <year>1981</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-10</page-range>
            <pub-id pub-id-type="pmid">6973117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Del Valle</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina: deficiency of ornithine aminotransferase in transformed lymphocytes.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1977</year>
            <month>Nov</month>
            <volume>74</volume>
            <issue>11</issue>
            <fpage>5159</fpage>
            <page-range>5159-61</page-range>
            <pub-id pub-id-type="pmid">270753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Nutrition and retinal degenerations.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2000</year>
            <season>Fall</season>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>93</fpage>
            <page-range>93-111</page-range>
            <pub-id pub-id-type="pmid">11064860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brody</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Obie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fontaine</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Sipila</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences.</article-title>
            <source>J Biol Chem</source>
            <year>1992</year>
            <month>Feb</month>
            <day>15</day>
            <volume>267</volume>
            <issue>5</issue>
            <fpage>3302</fpage>
            <page-range>3302-7</page-range>
            <pub-id pub-id-type="pmid">1737786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Steel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Milam</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2000</year>
            <month>Feb</month>
            <day>01</day>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>1224</fpage>
            <page-range>1224-9</page-range>
            <pub-id pub-id-type="pmid">10655512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Ibraheim</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Firoozmand</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina with hyperornithinaemia, cystinuria and lysinuria.</article-title>
            <source>Eye (Lond)</source>
            <year>1994</year>
            <volume>8 ( Pt 3)</volume>
            <fpage>284</fpage>
            <page-range>284-7</page-range>
            <pub-id pub-id-type="pmid">7958031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brusilow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Takki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina. Biochemical considerations and experience with an arginine-restricted diet.</article-title>
            <source>Ophthalmology</source>
            <year>1981</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>325</fpage>
            <page-range>325-30</page-range>
            <pub-id pub-id-type="pmid">7254778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Jonge</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Dingemanse</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lamers</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Moorman</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Arginine-metabolizing enzymes in the developing rat small intestine.</article-title>
            <source>Pediatr Res</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4 Pt 1</issue>
            <fpage>442</fpage>
            <page-range>442-51</page-range>
            <pub-id pub-id-type="pmid">9544996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whitcup</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Podgor</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sran</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Association of thyroid disease with retinitis pigmentosa and gyrate atrophy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>903</fpage>
            <page-range>903-5</page-range>
            <pub-id pub-id-type="pmid">8956655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renner</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiebig</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>J&#x000e4;gle</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy: clinical and genetic findings in a female without arginine-restricted diet during her first 39 years of life and report of a new OAT gene mutation.</article-title>
            <source>Doc Ophthalmol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-9</page-range>
            <pub-id pub-id-type="pmid">22674428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jasani</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>NRA</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Unique case of gyrate atrophy with a well-preserved electroretinogram (ERG).</article-title>
            <source>BMJ Case Rep</source>
            <year>2018</year>
            <month>Feb</month>
            <day>05</day>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">29437727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Ultrawide field fluorescein angiogram in a family with gyrate atrophy and foveoschisis.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2016</year>
            <season>May-Aug</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-6</page-range>
            <pub-id pub-id-type="pmid">27433038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic value of a combination of next-generation sequencing, chorioretinal imaging and metabolic analysis: lessons from a consanguineous Chinese family with gyrate atrophy of the choroid and retina stemming from a novel OAT variant.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>428</fpage>
            <page-range>428-435</page-range>
            <pub-id pub-id-type="pmid">30366948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moloney</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>O'Hagan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Ultrawide-field fundus photography of the first reported case of gyrate atrophy from Australia.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>1561</fpage>
            <page-range>1561-3</page-range>
            <pub-id pub-id-type="pmid">25187693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angio&#x000ef;-Duprez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maalouf</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>[Gyrate atrophy and craniopharyngioma: a case report].</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2001</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>513</fpage>
            <page-range>513-6</page-range>
            <pub-id pub-id-type="pmid">11397989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhioua Braham</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ammous</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Maalej</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boukari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mili Boussen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Errais</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhioua</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Multimodal imaging of foveoschisis and macular pseudohole associated with gyrate atrophy: a family report.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>12</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <pub-id pub-id-type="pmid">29649987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina diagnosed by ornithine-&#x003b4;-aminotransferase gene analysis: a case report.</article-title>
            <source>Korean J Ophthalmol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>388</fpage>
            <page-range>388-91</page-range>
            <pub-id pub-id-type="pmid">24082780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasconcelos-Santos</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Magalh&#x000e3;es</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Nehemy</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2007</year>
            <season>Sep-Oct</season>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>858</fpage>
            <page-range>858-61</page-range>
            <pub-id pub-id-type="pmid">18157315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shrestha</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pradhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>First reported cases of gyrate atrophy of the choroid from Nepal.</article-title>
            <source>BMJ Case Rep</source>
            <year>2010</year>
            <month>Nov</month>
            <day>29</day>
            <volume>2010</volume>
            <pub-id pub-id-type="pmid">22798087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alparslan</surname>
                <given-names>&#x0015e;</given-names>
              </name>
              <name>
                <surname>Fatih</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Muhammed</surname>
                <given-names>&#x0015e;</given-names>
              </name>
              <name>
                <surname>Adnan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Cystoid macular edema secondary to gyrate atrophy in a child treated with sub-tenon injection of triamcinolone acetonide.</article-title>
            <source>Rom J Ophthalmol</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-249</page-range>
            <pub-id pub-id-type="pmid">30505995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000e4;ntyj&#x000e4;rvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tuppurainen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Colour vision in gyrate atrophy.</article-title>
            <source>Vision Res</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>21</issue>
            <fpage>3409</fpage>
            <page-range>3409-12</page-range>
            <pub-id pub-id-type="pmid">9893857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bron</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical and biochemical heterogeneity in gyrate atrophy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1980</year>
            <month>Feb</month>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-22</page-range>
            <pub-id pub-id-type="pmid">7355975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Milam</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Steel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A mouse model of gyrate atrophy of the choroid and retina. Early retinal pigment epithelium damage and progressive retinal degeneration.</article-title>
            <source>J Clin Invest</source>
            <year>1996</year>
            <month>Jun</month>
            <day>15</day>
            <volume>97</volume>
            <issue>12</issue>
            <fpage>2753</fpage>
            <page-range>2753-62</page-range>
            <pub-id pub-id-type="pmid">8675686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratzlaff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baich</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of ornithine aminotransferase activities in the pigment epithelium and retina of vertebrates.</article-title>
            <source>Comp Biochem Physiol B</source>
            <year>1987</year>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-7</page-range>
            <pub-id pub-id-type="pmid">3677612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Cotlier</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Ornithine delta-aminotransferase activity in retina and other tissues.</article-title>
            <source>Neurochem Res</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-62</page-range>
            <pub-id pub-id-type="pmid">6462326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korte</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Reppucci</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Henkind</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>RPE destruction causes choriocapillary atrophy.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>10</issue>
            <fpage>1135</fpage>
            <page-range>1135-45</page-range>
            <pub-id pub-id-type="pmid">6480292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brusilow</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina: amino acid metabolism and correction of hyperornithinemia with an arginine-deficient diet.</article-title>
            <source>J Clin Invest</source>
            <year>1980</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>371</fpage>
            <page-range>371-8</page-range>
            <pub-id pub-id-type="pmid">7356686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valtonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>J&#x000e4;&#x000e4;skel&#x000e4;inen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hein&#x000e4;nen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alanen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heinonen</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Lundbom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Erkintalo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>855</fpage>
            <page-range>855-66</page-range>
            <pub-id pub-id-type="pmid">10604138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sipil&#x000e4;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rapola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sainio</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tuuteri</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina with hyperornithinemia: tubular aggregates and type 2 fiber atrophy in muscle.</article-title>
            <source>Neurology</source>
            <year>1979</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>996</fpage>
            <page-range>996-1005</page-range>
            <pub-id pub-id-type="pmid">572946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Weleber</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Ocular clinicopathologic study of gyrate atrophy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1991</year>
            <month>Jan</month>
            <day>15</day>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-33</page-range>
            <pub-id pub-id-type="pmid">1985486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valle</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Boison</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Jezyk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aguirre</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina in a cat.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1981</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>251</fpage>
            <page-range>251-5</page-range>
            <pub-id pub-id-type="pmid">7461927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valtonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hein&#x000e4;nen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alanen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalimo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Skeletal muscle of patients with gyrate atrophy of the choroid and retina and hyperornithinaemia in ultralow-field magnetic resonance imaging and computed tomography.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>1996</year>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>729</fpage>
            <page-range>729-34</page-range>
            <pub-id pub-id-type="pmid">8982944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliveira</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Muccioli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sallum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belfort</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cystoid macular edema in gyrate atrophy of the choroid and retina: a fluorescein angiography and optical coherence tomography evaluation.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>140</volume>
            <issue>1</issue>
            <fpage>147</fpage>
            <page-range>147-9</page-range>
            <pub-id pub-id-type="pmid">16038665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parameswarappa</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bilateral macular hole in gyrate atrophy: A rare association.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>652</fpage>
            <pub-id pub-id-type="pmid">32174595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inanc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tekin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Teke</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Bilateral choroidal neovascularization associated with gyrate atrophy managed with intravitreal bevacizumab.</article-title>
            <source>Int Ophthalmol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>1351</fpage>
            <page-range>1351-1355</page-range>
            <pub-id pub-id-type="pmid">28560651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peltola</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>J&#x000e4;&#x000e4;skel&#x000e4;inen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heinonen</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Falck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hein&#x000e4;nen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Peripheral nervous system in gyrate atrophy of the choroid and retina with hyperornithinemia.</article-title>
            <source>Neurology</source>
            <year>2002</year>
            <month>Sep</month>
            <day>10</day>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>735</fpage>
            <page-range>735-40</page-range>
            <pub-id pub-id-type="pmid">12221166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennaway</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Stankova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Weleber</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina: characterization of mutant ornithine aminotransferase and mechanism of response to vitamin B6.</article-title>
            <source>Am J Hum Genet</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>344</fpage>
            <page-range>344-52</page-range>
            <pub-id pub-id-type="pmid">2916580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valayannopoulos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Boddaert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mention</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Touati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbier</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chabli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sedel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dufier</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Seidenwurm</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rabier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saudubray</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>de Lonlay</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Secondary creatine deficiency in ornithine delta-aminotransferase deficiency.</article-title>
            <source>Mol Genet Metab</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-13</page-range>
            <pub-id pub-id-type="pmid">19345633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vannas-Sulonen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Progression of gyrate atrophy of the choroid and retina. A long-term follow-up by fluorescein angiography.</article-title>
            <source>Acta Ophthalmol (Copenh)</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-9</page-range>
            <pub-id pub-id-type="pmid">3577698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatziralli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Theodossiadis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emfietzoglou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Theodossiadis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal ranibizumab for choroidal neovascularization secondary to gyrate atrophy in a young patient: a multimodal imaging analysis.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2015</year>
            <month>Oct</month>
            <day>21</day>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>e119</fpage>
            <page-range>e119-22</page-range>
            <pub-id pub-id-type="pmid">26419008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Deutman</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Pinckers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Aandekerk</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy and choroidal neovascularization.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>114</volume>
            <issue>10</issue>
            <fpage>1295</fpage>
            <pub-id pub-id-type="pmid">8859105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salcedo-Villanueva</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paciuc-Beja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villanueva-Mendoza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harasawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Velez-Montoya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mandava</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Quiroz-Mercado</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Progression of gyrate atrophy measured with ultra-wide-field imaging.</article-title>
            <source>Int Ophthalmol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-120</page-range>
            <pub-id pub-id-type="pmid">26003990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raitta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vannas-Sulonen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina: ERG of the neural retina and the pigment epithelium.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>363</fpage>
            <page-range>363-7</page-range>
            <pub-id pub-id-type="pmid">2378845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weleber</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kennaway</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Buist</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina. Approaches to therapy.</article-title>
            <source>Int Ophthalmol</source>
            <year>1981</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>1-2</issue>
            <fpage>23</fpage>
            <page-range>23-32</page-range>
            <pub-id pub-id-type="pmid">7028650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina: further experience with long-term reduction of ornithine levels in children.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-53</page-range>
            <pub-id pub-id-type="pmid">11831916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sergouniotis</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Lenassi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devery</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Retinal structure, function, and molecular pathologic features in gyrate atrophy.</article-title>
            <source>Ophthalmology</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>596</fpage>
            <page-range>596-605</page-range>
            <pub-id pub-id-type="pmid">22182799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansour</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Elnahry</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Mehanna</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Vishal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>&#x000c7;avdarl&#x00131;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arrigo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parodi</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Analysis of optical coherence angiography in cystoid macular oedema associated with gyrate atrophy.</article-title>
            <source>Eye (Lond)</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1766</fpage>
            <page-range>1766-1774</page-range>
            <pub-id pub-id-type="pmid">32873946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raval</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Optical Coherence Tomography Angiography and Macular Vessel Density Analysis of Cystoid Macular Edema in Gyrate Atrophy.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>423</fpage>
            <page-range>423-427</page-range>
            <pub-id pub-id-type="pmid">31344241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McInnes</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Arshinoff</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McCulloch</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of gyrate atrophy of the choroid and retina with low arginine diet.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>1980</year>
            <volume>78</volume>
            <fpage>226</fpage>
            <page-range>226-42</page-range>
            <pub-id pub-id-type="pmid">7257057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mashima</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Weleber</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kennaway</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Inana</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Genotype-phenotype correlation of a pyridoxine-responsive form of gyrate atrophy.</article-title>
            <source>Ophthalmic Genet</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>219</fpage>
            <page-range>219-24</page-range>
            <pub-id pub-id-type="pmid">10617919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santinelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Costagliola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tolone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D'Aloia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Avanzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prisco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>del Giudice</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Low-protein diet and progression of retinal degeneration in gyrate atrophy of the choroid and retina: a twenty-six-year follow-up.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2004</year>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-96</page-range>
            <pub-id pub-id-type="pmid">15159649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vannas-Sulonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sipil&#x000e4;</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina. The ocular disease progresses in juvenile patients despite normal or near normal plasma ornithine concentration.</article-title>
            <source>Ophthalmology</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>94</volume>
            <issue>11</issue>
            <fpage>1428</fpage>
            <page-range>1428-33</page-range>
            <pub-id pub-id-type="pmid">3684217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ros</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Nuts and CVD.</article-title>
            <source>Br J Nutr</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>113 Suppl 2</volume>
            <fpage>S111</fpage>
            <page-range>S111-20</page-range>
            <pub-id pub-id-type="pmid">26148914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michaud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Brody</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Steel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Obie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fontaine</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schappert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Keith</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine-responsive gyrate atrophy of the choroid and retina: clinical and biochemical correlates of the mutation A226V.</article-title>
            <source>Am J Hum Genet</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>616</fpage>
            <page-range>616-22</page-range>
            <pub-id pub-id-type="pmid">7887415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayasaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroid and retina.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-90</page-range>
            <pub-id pub-id-type="pmid">3922397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Javadzadeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gharabaghi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina with hyper-ornithinemia responsive to vitamin B6: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2007</year>
            <month>Jun</month>
            <day>12</day>
            <volume>1</volume>
            <fpage>27</fpage>
            <pub-id pub-id-type="pmid">17565677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sipil&#x000e4;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rapola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vannas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina.</article-title>
            <source>N Engl J Med</source>
            <year>1981</year>
            <month>Apr</month>
            <day>09</day>
            <volume>304</volume>
            <issue>15</issue>
            <fpage>867</fpage>
            <page-range>867-70</page-range>
            <pub-id pub-id-type="pmid">7207523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vannas-Sulonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sipil&#x000e4;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vannas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simell</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rapola</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of the choroid and retina. A five-year follow-up of creatine supplementation.</article-title>
            <source>Ophthalmology</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>12</issue>
            <fpage>1719</fpage>
            <page-range>1719-27</page-range>
            <pub-id pub-id-type="pmid">4088625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casalino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pierro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manitto</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Michaelides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Resolution of cystoid macular edema following arginine-restricted diet and vitamin B6 supplementation in a case of gyrate atrophy.</article-title>
            <source>J AAPOS</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-323</page-range>
            <pub-id pub-id-type="pmid">29654911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c7;avdarl&#x00131;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>&#x0015e;ahl&#x00131;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000c7;avdarl&#x00131;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alp</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-152</page-range>
            <pub-id pub-id-type="pmid">32159596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piozzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alessi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santambrogio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cillino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iggui</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cillino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Carbonic Anhydrase Inhibitor with Topical NSAID Therapy to Manage Cystoid Macular Edema in a Case of Gyrate Atrophy.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2017</year>
            <month>Nov</month>
            <day>08</day>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>e179</fpage>
            <page-range>e179-e183</page-range>
            <pub-id pub-id-type="pmid">28708224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elnahry</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Letter to the editor regarding: "cystoid macular edema secondary to gyrate atrophy in a child treated with sub-tenon injection of triamcinolone acetonide".</article-title>
            <source>Rom J Ophthalmol</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-318</page-range>
            <pub-id pub-id-type="pmid">30891531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelmassih</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>El-Khoury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cherfan</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Dexamethasone implant for the treatment of gyrate atrophy associated macular edema.</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e4</page-range>
            <pub-id pub-id-type="pmid">30559013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elnahry</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Aboulfotouh</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Nassar</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Intraretinal Cystic Spaces Associated With Gyrate Atrophy of the Choroid and Retina With Intravitreal Bevacizumab.</article-title>
            <source>J Pediatr Ophthalmol Strabismus</source>
            <year>2020</year>
            <month>Nov</month>
            <day>01</day>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>400</fpage>
            <page-range>400-406</page-range>
            <pub-id pub-id-type="pmid">33211898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsilou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bilateral late posterior chamber intraocular lens dislocation with the capsular bag in a patient with gyrate atrophy.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>1593</fpage>
            <page-range>1593-4</page-range>
            <pub-id pub-id-type="pmid">15210246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berbel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Rauen</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Pallone</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Casella</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Retinal detachment and gyrate atrophy of the choroid and retina: case report.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-60</page-range>
            <pub-id pub-id-type="pmid">22552420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahashi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hayasaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kiyosawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy of choroid and retina complicated by vitreous hemorrhage.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>1985</year>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-6</page-range>
            <pub-id pub-id-type="pmid">4046225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Radziwon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>St Laurent</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Choroideremia.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>410</fpage>
            <page-range>410-415</page-range>
            <pub-id pub-id-type="pmid">28520608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verbakel</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>van Huet</surname>
                <given-names>RAC</given-names>
              </name>
              <name>
                <surname>Boon</surname>
                <given-names>CJF</given-names>
              </name>
              <name>
                <surname>den Hollander</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Collin</surname>
                <given-names>RWJ</given-names>
              </name>
              <name>
                <surname>Klaver</surname>
                <given-names>CCW</given-names>
              </name>
              <name>
                <surname>Hoyng</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Roepman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klevering</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Non-syndromic retinitis pigmentosa.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>66</volume>
            <fpage>157</fpage>
            <page-range>157-186</page-range>
            <pub-id pub-id-type="pmid">29597005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Audo</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>45</volume>
            <fpage>58</fpage>
            <page-range>58-110</page-range>
            <pub-id pub-id-type="pmid">25307992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molday</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Kellner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2012</year>
            <month>May</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-212</page-range>
            <pub-id pub-id-type="pmid">22245536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Garc&#x000ed;a</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Rubio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moya-Moya</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Santonja</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Escribano</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Current perspectives in Bietti crystalline dystrophy.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>1379</fpage>
            <page-range>1379-1399</page-range>
            <pub-id pub-id-type="pmid">31440027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pigmented Paravenous Chorioretinal Atrophy (PPCRA).</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2018</year>
            <volume>1085</volume>
            <fpage>111</fpage>
            <page-range>111-113</page-range>
            <pub-id pub-id-type="pmid">30578495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godley</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Tiffin</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kelsell</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of progressive bifocal chorioretinal atrophy: a retinal dystrophy linked to chromosome 6q.</article-title>
            <source>Ophthalmology</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>893</fpage>
            <page-range>893-8</page-range>
            <pub-id pub-id-type="pmid">8643244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elnahry</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Khafagy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Esmat</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mortada</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and Associations of Posterior Segment Manifestations in a Cohort of Egyptian Patients with Pathological Myopia.</article-title>
            <source>Curr Eye Res</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>9</issue>
            <fpage>955</fpage>
            <page-range>955-962</page-range>
            <pub-id pub-id-type="pmid">30964360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Fundus autofluorescence, optical coherence tomography, and electroretinogram findings in choroidal sclerosis.</article-title>
            <source>Retina</source>
            <year>2010</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>1095</fpage>
            <page-range>1095-103</page-range>
            <pub-id pub-id-type="pmid">20224472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kellner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Weleber</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kennaway</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Foerster</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy-like phenotype with normal plasma ornithine.</article-title>
            <source>Retina</source>
            <year>1997</year>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>403</fpage>
            <page-range>403-13</page-range>
            <pub-id pub-id-type="pmid">9355188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Labiano</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Arroyo</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Gyrate atrophy-like phenotype with normal plasma ornithine and low plasma taurine.</article-title>
            <source>GMS Ophthalmol Cases</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>Doc04</fpage>
            <pub-id pub-id-type="pmid">32269902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93879.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ultra-wide Field Imaging of an Operated Macular Hole in Gyrate Atrophy.</article-title>
            <source>J Ophthalmic Vis Res</source>
            <year>2016</year>
            <season>Jul-Sep</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>336</fpage>
            <page-range>336-7</page-range>
            <pub-id pub-id-type="pmid">27621797</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
